RBC Europe’s Galectin Therapeutics GALT Stock Holding History

RBC Europe’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40	Closed	-$155	–	815
2021 Q3	$155	Hold	40	–	–	﹤0.01%	1216
2021 Q2	$128	Hold	40	–	–	﹤0.01%	1210
2021 Q1	$87	Hold	40	–	–	﹤0.01%	1164
2020 Q4	$90	Hold	40	–	–	﹤0.01%	1134
2020 Q3	$107	Hold	40	–	–	﹤0.01%	1079
2020 Q2	$122	Hold	40	–	–	﹤0.01%	1040
2020 Q1	$78	Hold	40	–	–	﹤0.01%	1023
2019 Q4	$114	Hold	40	–	–	﹤0.01%	1031
2019 Q3	$147	Hold	40	–	–	﹤0.01%	1028
2019 Q2	$166	Hold	40	–	–	﹤0.01%	1043
2019 Q1	$204	Hold	40	–	–	﹤0.01%	1054
2018 Q4	$137	Hold	40	–	–	﹤0.01%	1067
2018 Q3	$240	Hold	40	–	–	﹤0.01%	1103
2018 Q2	$254	Hold	40	–	–	﹤0.01%	1114
2018 Q1	$190	Hold	40	–	–	﹤0.01%	1095
2017 Q4	$134	Hold	40	–	–	﹤0.01%	1115
2017 Q3	$86	Buy	+40	New	+$79	﹤0.01%	1122

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RBC Europe's GALT Position: Q4 2021 in Review

RBC Europe sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 40 shares — an estimated $155 sold.

RBC Europe first reported a position in GALT in Q3 2017 and held it in 17 quarters. The position peaked at $254 in Q2 2018. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

RBC Europe reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 40 Galectin Therapeutics shares in Q4 2021, an estimated $155.
RBC Europe first reported a position in Galectin Therapeutics in Q3 2017 and held it in 17 quarters.
RBC Europe's Galectin Therapeutics position peaked at $254 in Q2 2018.
55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.